Sequence diversity of kappa light chains from patients with AL amyloidosis and multiple myeloma.

AL amyloidosis Ig-kappa light chain LC sequence immunoglobulin light chain multiple myeloma

Journal

Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis
ISSN: 1744-2818
Titre abrégé: Amyloid
Pays: England
ID NLM: 9433802

Informations de publication

Date de publication:
11 Jan 2024
Historique:
medline: 11 1 2024
pubmed: 11 1 2024
entrez: 11 1 2024
Statut: aheadofprint

Résumé

AL amyloidosis (AL) results from the misfolding of immunoglobulin light chains (IG LCs). Aim of this study was to comprehensively analyse kappa LC sequences from AL patients in comparison with multiple myeloma (MM). We analysed cDNA and bulk RNA sequencing of the LCs of AL and MM patients. We studied 41 AL and 83 MM patients showing that This study confirmed that germline usage has an influence on AL amyloidosis risk and organ involvement.

Sections du résumé

BACKGROUND UNASSIGNED
AL amyloidosis (AL) results from the misfolding of immunoglobulin light chains (IG LCs). Aim of this study was to comprehensively analyse kappa LC sequences from AL patients in comparison with multiple myeloma (MM).
OBJECTIVE UNASSIGNED
We analysed
MATERIAL AND METHODS UNASSIGNED
cDNA and bulk RNA sequencing of the LCs of AL and MM patients.
RESULTS UNASSIGNED
We studied 41 AL and 83 MM patients showing that
CONCLUSION UNASSIGNED
This study confirmed that germline usage has an influence on AL amyloidosis risk and organ involvement.

Identifiants

pubmed: 38206120
doi: 10.1080/13506129.2023.2295221
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-9

Auteurs

Sarah Schreiner (S)

Medical Department V, Amyloidosis Center, Heidelberg University Hospital, Heidelberg, Germany.

Natalie Berghaus (N)

Medical Department V, Amyloidosis Center, Heidelberg University Hospital, Heidelberg, Germany.

Alexandra M Poos (AM)

Medical Department V, Heidelberg Myeloma Center, Heidelberg University Hospital, Germany.

Marc S Raab (MS)

Medical Department V, Heidelberg Myeloma Center, Heidelberg University Hospital, National Centre for Tumor Diseases (NCT), Heidelberg, Germany.

Britta Besemer (B)

Department of Internal Medicine II, Tübingen University Hospital, Tübingen, Germany.

Roland Fenk (R)

Department of Hematology, Oncology, and Clinical Immunology, Düsseldorf University Hospital, Düsseldorf, Germany.

Hartmut Goldschmidt (H)

Medical Department V, Heidelberg Myeloma Center, Heidelberg University Hospital, National Centre for Tumor Diseases (NCT), Heidelberg, Germany.

Elias K Mai (EK)

Medical Department V, Heidelberg Myeloma Center, Heidelberg University Hospital, National Centre for Tumor Diseases (NCT), Heidelberg, Germany.

Carsten Müller-Tidow (C)

Medical Department V, Heidelberg University Hospital, Heidelberg, Germany.

Niels Weinhold (N)

Medical Department V, Heidelberg Myeloma Center, Heidelberg University Hospital, Germany.

Ute Hegenbart (U)

Medical Department V, Amyloidosis Center, Heidelberg University Hospital, Heidelberg, Germany.

Stefanie Huhn (S)

Medical Department V, Heidelberg Myeloma Center, Heidelberg University Hospital, Germany.

Stefan O Schönland (SO)

Medical Department V, Amyloidosis Center, Heidelberg University Hospital, Heidelberg, Germany.

Classifications MeSH